MARKET OVERVIEW- GLOBAL EQUILIBRIUM DIALYSIS MARKET
The global equilibrium dialysis market was valued at USD 156.24 Million in 2022 and is projected to grow at a CAGR of 9.49 % for the forecast period 2023 to 2029. The global market is estimated and forecasted in terms of revenue (USD Million) generated by the equilibrium dialysis market.
Equilibrium dialysis assists in quantifying the binding of small molecule drug candidates to proteins. These methods are widely used in drug discovery and manufacturing processes. The extent of binding of the drug to proteins, which is determined by measuring the free active fraction. Equilibrium dialysis technique is crucial procedure in estimating the drug binding capacity of various macromolecules in the early stages of drug discovery and in clinical trials. Equilibrium dialysis is among the most widely used methods for evaluating protein binding and can be performed using a rapid equilibrium dialysis device. Researchers prefer this method because it has fewer binding effects on extraneous and unintended factors affecting research results. Various advantages of equilibrium dialysis including high accuracy, low cost and reliability, are attributed to the high revenue share of this segment. In addition, the equilibrium dialysis workflow is simple, making this technology the preferred choice for determining the protein binding capacity of a drug under study. This further contributes to the revenue growth ahead for the equilibrium dialysis market.
MARKET DRIVERS
Increasing focus on new drug discovery and development processes and rapid developments in the pharmaceutical and biotechnological industries are primary factors fuelling global equilibrium dialysis market revenue growth. Drug discovery and development require large investments including technical experts, capital, and human resources. For example, according to Pharmaceutical Research and Manufacturers of America, in 2020 the U.S. pharmaceutical industry’s expenditure on research and development was USD 91.1 billion, which has since increased to USD 102.3 billion. These factors are expected to drive revenue growth in the global equilibrium dialysis market. Further, in advanced healthcare regulatory scenarios, a surge in funding for healthcare infrastructure, high investment in research and development and the expansion of the biotechnology sector will positively affect the global equilibrium dialysis market.
MARKET OPPORTUNITIES
The new technologies to identify and screen drug candidates for novel drug development. Novel drug developments allow research personnel to tap into previously untargeted segments of chronic, degenerative and life-threatening diseases. Many pharmaceutical and biopharmaceutical research companies are rechecking their old R&D policies and focusing their efforts on improving efficiency, performance, and meeting patient needs due to current economic and political pressures to reduce healthcare costs. Hence, the development of novel drugs for rear diseases and other diseases creates an opportunity for the growth of the market.
MARKET RESTRAINTS
The availability of alternate techniques is expected to limit the growth of the market. The introduction of advanced methodologies including an in situ protein-protein interaction assay that is highly sensitive compared to conventional techniques, has posed a threat to market growth. Additionally, adoption of parallel testing techniques for assay analysis can be more effective than the equilibrium dialysis technique. The affective technologies are alternatives to equilibrium dialysis. Hence, a boost in the adoption of these assays in laboratories would, hinder the growth of the equilibrium dialysis market.
MARKET GROWTH CHALLENGES
High investment costs for drug discovery is among major challenging factor affecting the market growth. Drug discovery and development are healthy investments, drug discovery require advanced technologies, establishment costs, and skilled human resources. Protein binding assays, and equilibrium dialysis are among the major methodologies involved in drug discovery. Both the protein binding assays are capable of optimizing cost by increasing the abortion capabilities during the pre-clinical phase. This reduces attrition during the final stages of drug development. The aforementioned cons of equilibrium dialysis are expected to challenge the global equilibrium dialysis market in the foreseen period.
CUMULATIVE GROWTH ANALYSIS
The report provides an in-depth analysis of the global equilibrium dialysis market, including market size, and compound annual growth rate (CAGR) for the forecast period of 2023-2029, considering 2022 as the base year. The increased demand for drug discovery is expected to witness growth at a specific CAGR from 2023-2029.
EQUILIBRIUM DIALYSIS MARKET SEGMENTAL OVERVIEW
The Global Equilibrium Dialysis Market consists of different market segments like By Type, By Product, Application, End-Users, and geography.
EQUILIBRIUM DIALYSIS MARKET BY TYPE
The Equilibrium Dialysis market on the basis of type include:
- Linear Regression
- Non-Linear Regression
The nonlinear regression segment is expected to witness high growth over the estimated time period. While nonlinear regression models differ from linear regression models in that the least-squares estimators of their parameters are not unbiased, normally distributed. Such flexibility provides a good basis on which to make statistical inferences. Thus, the non-linear regression method is expected to dominate the market over the forecast period.
EQUILIBRIUM DIALYSIS MARKET BY PRODUCT TYPE
The Equilibrium Dialysis market on the basis of Product include:
- Instrument
- Kits and Reagents
The instrument segment is expected to witness high growth over the estimated time period. Equilibrium dialysis instruments have been used to measure drug protein binding. This technique involves equilibrating a drug-rich plasma sample with a drug-free buffer across the membrane, allowing free drug to migrate across the membrane and preventing protein-bound drug transfer into the buffer. This equilibrium is reached in more than 24 hours. Other techniques, such as rapid equilibrium dialysis, further reduce the workflow time from >24 hours to 6 hours using specially designed devices. Therefore, nowadays, the rapid equilibrium dialysis instrument is being used on a large scale for several applications.
EQUILIBRIUM DIALYSIS MARKET BY END-USERS
The Equilibrium Dialysis market on the end-users of include:
- Contract Research Organizations
- Biotechnology Companies
- Pharmaceutical
On the basis of end-users, the contract research organization segment holds the largest share of the equilibrium dialysis market. The contract research organization is mainly driven by the need for cost effective protein binding services. Contract research organization (CROs) services have become more prevalent within the healthcare industry. There have been substantial advancements in the healthcare field, including research and drug development. Due to this factor, the contract research organizations segment is expected to lead the market during the estimated time period. This is expected to accelerate the demand for the equilibrium dialysis market.
EQUILIBRIUM DIALYSIS MARKET BY APPLICATION
The Equilibrium Dialysis market on the basis of application include:
- Protein-Drug Binding Assays
- Receptor Binding Assays
- Ligand Binding Assays
- Protein-Protein Interactions
- Protein-DNA Interactions
- Serum Protein Binding
Based on application, the protein-drug binding assays segment holds the largest share of the equilibrium dialysis market. Pharmaceutical companies and regulatory agencies are interested in determining the extent of drug binding to plasma and tissue proteins early in the drug development process. Scientists and researchers measure the binding of drug components to plasma or tissue proteins by using different methods. Due to these key advantages, the protein-drug binding assays segment is expected to dominate the market over the projected time period, which will increase demand for the equilibrium dialysis market.
EQUILIBRIUM DIALYSIS MARKET BY GEOGRAPHY
The Equilibrium Dialysis market is studied for the following region:
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
For the equilibrium dialysis market, North America is expected to witness the largest share in the equilibrium dialysis market. North America dominates the equilibrium dialysis market due to the increased i presence of key players and increased funding from public and private entities, which has expanded drug discovery and development. Increased the amount of expenditure spent on the advancement of technologies available for drug development in the U.S region. For example. According to the U.S. Food and Drug Administrative FDA in 2018, 59 novel drugs were approved by Centre for Drug Evaluation and Research (CDER), as compared to 46 new drugs approved in 2017. Therefore, an increase in the number of drug candidates being screened and approved annually, is driving the adoption of equilibrium dialysis.
Asia Pacific is an expected region for growth of the equilibrium dialysis market due to the increase in the availability of a number of advanced technologies used for protein binding in the region, which has led to an increase in the demand for equilibrium dialysis in the region.
COVID-19 IMPACT ANALYSIS ON THE GLOBAL EQUILIBRIUM DIALYSIS MARKET
Axiom MRC provides a 360-degree analysis of the micro and macro-economic factors of the equilibrium dialysis market. The report included an exclusive analysis of the impact of COVID-19. In addition, the report also studied a complete analysis of changes in the global equilibrium dialysis market, spending, and economic and international policies on the supply and demand side. COVID 19 has significantly impacted the global revenue of the equilibrium dialysis market. Vaccine development and progress in the drug supply chain have accelerated due to the COVID-19 outbreak. The total consumer spending on healthcare has witnessed a decline during COVID-19. According IMF (Indian Monetary Fund), the per capita consumer spending on healthcare in USD 4,861.22 Billion in 2019, which has decreased to USD 4,671.43 in 2020, and has increased to USD 5,173.41 Billion in 2021. The data depicts the effect of COVID-19 on the healthcare industry including the equilibrium dialysis market. However, the high demand for drugs presented huge opportunities for drug makers to treat COVID-19 as many regions faced drug shortages.
COMPETITIVE LANDSCAPE ANALYSIS
The competitive landscape analysis of the equilibrium dialysis is primarily focused on expanding the global growth of equilibrium dialysis market with new type innovation, business expansion, and the increasing presence of a range of manufacturers operating in the equilibrium dialysis market has led to growing demand for the market.
The key players studied in the market are
- Harvard Apparatus (United States)
- Thermo Fisher (Unites States)
- The Nest Group, Inc. (Unites States)
- Aurora Borealis Control BV (Netherland)
- Vivaproducts (United States)
- Cole-Parmer (United States)
- Absorption Systems LLC (United States)
- Interchim (France)
- Creative Biolabs (United States)
- Bioduro-Sundia (China)
RECENT DEVELOPMENT:
June 2020: Thermo Fisher Scientific has partnered with Genetron Holdings Limited to build on the sequencer Genetron. The partnership is expected to boost revenue for both Thermo Fisher Scientific and Genetron Holdings Limited.
May 2022: Thermo Fisher Scientific has partnered with a company named LabShares to support its research and development activities. The partnership is expected to bring better products owing to efficient research and development.
September 2016: Thermo Fisher Scientific has partnered with Mindray to enhance the clinical chemistry analysers that can be used for immunoassays.
